載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$1.53
−US$0.04 · -2.55%
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
前收盤價
US$1.53
−US$0.04 · -2.55%
盤中時間採用ET。市場資料可能有所延遲。
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
日內區間
目前US$1.53
52週區間
目前US$1.53
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
47
合理估值
情緒
45
多空交錯
風險
60
風險偏高
動能
30
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
日內區間
目前US$1.53
52週區間
目前US$1.53
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 7.57億 EUR | 7.97億 EUR | 7.81億 EUR | 7.51億 EUR | 6.18億 EUR |
| 銷貨成本 | 6.95億 EUR | 6.82億 EUR | 6.06億 EUR | 5.77億 EUR | 4.66億 EUR |
| 毛利 | 6266.23萬 EUR | 1.15億 EUR | 1.75億 EUR | 1.74億 EUR | 1.52億 EUR |
| 研究與開發 | 7432.89萬 EUR | 5085.7萬 EUR | 6852.9萬 EUR | 7664.2萬 EUR | 6569.8萬 EUR |
| 銷售、一般及管理費用 | 1.24億 EUR | 1.88億 EUR | 1.7億 EUR | 1.56億 EUR | 1.05億 EUR |
| 營業費用 | 1.98億 EUR | 2.57億 EUR | 2.23億 EUR | 1.53億 EUR | 1.11億 EUR |
| 利息收入 | 424.94萬 EUR | 243.5萬 EUR | 926.3萬 EUR | 833.6萬 EUR | 227.2萬 EUR |
| 利息支出 | 1387.2萬 EUR | 1169.9萬 EUR | 1173.9萬 EUR | 1315萬 EUR | 925.4萬 EUR |
| 折舊和攤銷 | 9555萬 EUR | 1.02億 EUR | 9297.9萬 EUR | 8319.6萬 EUR | 7039.9萬 EUR |
| 營業利益 | −1.35億 EUR | −1.43億 EUR | −4750.7萬 EUR | 2085萬 EUR | 4099.6萬 EUR |
| 淨利 | −9943.15萬 EUR | −1.96億 EUR | −8391.3萬 EUR | −1.76億 EUR | 2.16億 EUR |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$3.00
上漲空間 96.08%年度分割調整後的每股現金分配。
US$0.5412
2018年（完整年度）-6.0% 自從 2017
US$0.576
2,017
US$0.5412
2,018
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2019年1月11日 | US$0.2888Monthly | — | — |
股息 | 2018年12月12日 | US$0.1804Monthly | — | — |
股息 | 2018年11月8日 | US$0.1804Monthly | — | — |
股息 | 2018年10月10日 | US$0.1804Monthly | — | — |
股息 | 2018年9月13日 | US$0.1804Monthly | — | — |
股息 | 2018年8月10日 | US$0.1804Monthly | — | — |
除息 2019年1月11日
US$0.2888
Monthly
除息 2018年12月12日
US$0.1804
Monthly
除息 2018年11月8日
US$0.1804
Monthly
除息 2018年10月10日
US$0.1804
Monthly
除息 2018年9月13日
US$0.1804
Monthly
除息 2018年8月10日
US$0.1804
Monthly
報告持有此股票曝險的交易所交易基金。
John Hancock Investments - Multifactor Developed International ETFJHMD
State Street SPDR MSCI World StrategicFactors ETFQWLD
Applied Finance IVS International Large ETFIVSIAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
